Efficacy and Safety of Xinglou Chengqi Granule for Acute Ischemic Stroke
ConditionAcute Ischemic Stroke
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-70
SponsorDongzhimen Hospital, Beijing
About this trial
This is a Ⅱa clinical trial. The purpose of this study is to preliminarily explore the optimal dosage of Xinglou Chengqi Granules in the treatment of acute ischemic stroke and to evaluate the efficacy and safety of Xinglou Chengqi Granules for acute ischemic stroke.
Eligibility criteria
Qualifiers
Inpatients diagnosed with acute ischemic stroke.
Meet the criteria of TCM phlegm-heat and fu-organ excess syndrome.
Acute ischemic stroke within 7 days after onset.
6 ≤ NIHSS <20.
Disqualifiers
Suspected secondary stroke caused by brain tumor, brain trauma, hemopathy, etc.
NIHSS Ⅰa ≥2.
Already dependent in activities of daily living before the present acute stroke (defined as modified Rankin Scare score ≥2 )
Received or planned thrombolysis or endovascular therapy after onset.
Trial design
Treatments tested in this trial
- High-dose Xinglou Chengqi granules
- Low-dose Xinglou Chengqi granules and placebo
Treatment groups
60 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov